reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
== Use in agriculture == Plant regulators (PRs) or plant growth regulators (PGRs) are compounds, both naturally occurring and synthetic, used in agriculture to modify the behaviour of plants. They can be used to increase or inhibit growth, influence flowering and/or fruit growth, alter the maturation, or reduce abiotic stress. The compendium of pesticide common names lists 103 plant growth regulators, many of which have been removed from the market. When used in field conditions, plant hormones or mixtures that include them can be applied as biostimulants.
=== Distribution === Ceftriaxone penetrates tissues and body fluids well, including cerebrospinal fluid to treat central nervous system infections. Ceftriaxone is reversibly bound to human plasma proteins and the binding of ceftriaxone decreases with increasing concentration from a value of 95% at plasma concentrations less than 25 mcg/mL to 85% at plasma concentration of 300 mcg/mL. Over a 0.15 to 3 g dose range in healthy adult subjects, the apparent volume of distribution ranged from 5.8 to 13.5 L.
KefB/KefC K+ efflux proteins of E. coli (i.e., TC# 2.A.37.1.3 and TC# 2.A.37.1.1, respectively), which may be capable of catalyzing both K+/H+ antiport and K+ uniport, depending on conditions Na+/H+ antiporter of Enterococcus hirae (i.e., NapA, TC# 2.A.37.2.1) K+/H+ antiporter of S. cerevisiae (i.e., Kha1, TC# 2.A.37.4.1). It has been proposed that under normal physiological conditions, these proteins may function by essentially the same mechanism. KefC and KefB of E. coli are responsible for glutathione-gated K+ efflux. Each of these proteins consists of a transmembrane hydrophobic N-terminal domain, and a lesser conserved C-terminal hydrophilic domain. Each protein interacts with a second protein encoded by genes that overlap the gene encoding the primary transporter. The KefC ancillary protein is YabF while the KefB ancillary protein is YheR. These ancillary proteins stimulate transport activity about 10-fold. These proteins are important for cell survival during exposure to toxic metabolites, possibly because they can release K+, allowing H+ uptake. Activation of the KefB or KefC K+ efflux system only occurs in the presence of glutathione and a reactive electrophile such as methylglyoxal or N-ethylmaleimide. Formation of the methylglyoxal-glutathione conjugate, S-lactoylglutathione, is catalyzed by glyoxalase I, and S-lactoylglutathione activates KefB and KefC. H+ uptake (acidification of the cytoplasm) accompanying or following K+ efflux may serve as a further protective mechanism against electrophile toxicity.
=== Mechanical properties === α-Helices under axial tensile deformation, a characteristic loading condition that appears in many alpha-helix-rich filaments and tissues, results in a characteristic three-phase behavior of stiff-soft-stiff tangent modulus. Phase I corresponds to the small-deformation regime during which the helix is stretched homogeneously, followed by phase II, in which alpha-helical turns break mediated by the rupture of groups of H-bonds. Phase III is typically associated with large-deformation covalent bond stretching.
== External links == Kristin Tillotson, "Minnesota Opera co-commissions Cold Mountain, Minneapolis Star Tribune (Artcetera blog), 6 May 2014 Heidi Waleson, "Creating Cold Mountain: Student Singers Help to Shape a Major Modern Opera", Overtones (Curtis Institute of Music), Spring 2014 Cold Mountain, Opera Philadelphia page "Cold Mountain makes East Coast Premiere February 5–14, 2016, at the Academy of Music." Opera Philadelphia press release, 5 January 2016 Tom Huizenga, "Great Expectations: A New Season Of New Music". National Public Radio (Deceptive Cadence blog), 3 September 2014 "Jennifer Higdon writes an opera", The Musicalist podcast, 12 February 2014 Jim Cotter, "Jennifer Higdon on Cold Mountain". WRTI, 90.1 FM, 16 November 2012 Mark Gresham, "Jennifer Higdon completes her new opera, Cold Mountain". EarRelevant blog, 17 September 2013 Pentatone Records page on Cold Mountain Peter Dobrin, "Cold Mountain scores", The Philadelphia Inquirer, Blogs the Arts, 16 May 2016
Sources: en.wikipedia.org
== Physical activity == The Global Matrix 2.0 on Physical Activity for Children and Youth (2016) gave Thailand a score of D-minus (A=best, B-C-D, F=worst). The only other ASEAN country in the study of 38 nations was Malaysia, which received a score of D.
== Description == The emu is the second tallest bird in the world, only being exceeded in height by the ostrich; the largest individuals can reach up to 150 to 190 cm (59 to 75 in) in height. Measured from the bill to the tail, emus range in length from 139 to 164 cm (55 to 65 in), with males averaging 148.5 cm (58.5 in) and females averaging 156.8 cm (61.7 in). Emus are the fourth or fifth heaviest living bird after the two species of ostrich and two larger species of cassowary, weighing slightly more on average than an emperor penguin. Adult emus weigh between 18 and 60 kg (40 and 132 lb), with an average of 31.5 and 37 kg (69 and 82 lb) in males and females, respectively. Females are usually slightly larger than males and are substantially wider across the rump.
Vaccination against mumps did not become routine until Mumpsvax was included in Merck's combined MMR vaccine, which targeted measles and rubella along with mumps. MMR was licensed in 1971, and 40 percent of American children had received the combined vaccine by 1974. In 1977, the U.S. Centers for Disease Control and Prevention (CDC) recommended mumps immunization (as part of MMR) for all children over 12 months of age, and in 1998, CDC began recommending a two-dose immunization of MMR.
=== Other locations === Every Halloween since 1969, a pumpkin has been impaled onto the spire of North Miami Public Library by a group named Coxie's Army. This has become a celebrated tradition, and is often accompanied by the hanging of a poem at the library's entrance. At the University of Montana, a pumpkin has been placed on the spire of the Main Hall every October since 1995. These pranks resulted in arrests on charges of trespassing in 2004 and 2016.
=== A Beautiful Mind === In 1959, the 1994 Nobel Prize winner in Economics, John Nash, was diagnosed with schizophrenia and was initially treated at McLean Hospital. When he relapsed, he was admitted to Trenton Psychiatric Hospital in New Jersey. His associates at Princeton University pleaded with the hospital director to have Nash admitted to the insulin coma unit, recognizing that it was better staffed than other hospital units. He responded to treatment and was subsequently medicated with neuroleptics. Nash's life story was presented in the film A Beautiful Mind, which accurately portrayed the seizures associated with his treatments. In a review of the Nash history, Fink ascribed the success of coma treatments to the 10% of associated seizures, noting that physicians often augmented the comas by convulsions induced by ECT. He envisioned insulin coma treatment as a weak form of convulsive therapy.
Sources: en.wikipedia.org
Teleosts possess highly developed sensory organs. Nearly all daylight fish have colour vision at least as good as a normal human's. Many fish also have chemoreceptors responsible for acute senses of taste and smell. Most fish have sensitive receptors that form the lateral line system, which detects gentle currents and vibrations, and senses the motion of nearby fish and prey. Fish sense sounds in a variety of ways, using the lateral line, the swim bladder, and in some species the Weberian apparatus. Fish orient themselves using landmarks, and may use mental maps based on multiple landmarks or symbols. Experiments with mazes show that fish possess the spatial memory needed to make such a mental map.
== Prognosis == Diabulimia appears to lower life expectancy compared to other patients with type 1 diabetes, with the mean age of death around 45 (13 years lower than that for type 1 diabetes without an eating disorder). This reduced life expectancy is correlated with the severity of eating disorder behaviors.
Electrical charges have been omitted for simplicity of notation. The square brackets indicate concentration, and the subscripts to the stability constants, β, indicate the stoichiometry of the complex. When the analytical concentration of methylamine is twice that of ethylenediamine and the concentration of copper is the same in both reactions, the concentration [Cd(en)] is much higher than the concentration [Cd(MeNH2)2] because β11 ≫ β12. An equilibrium constant, K, is related to the standard Gibbs free energy,
== History == Cold hemagglutination was first reported by Landsteiner in 1903 and found to occur in human beings in 1918. The association of cold hemagglutination with hemolysis was described in 1937 by Rosenthal and Corten. During the 1960s, Dacie and Schubothe published systematic descriptions of 16 CAD patients each. The auto antibodies responsible for hemagglutination at low temperatures, cold agglutinins (CA), may be found in the sera of healthy subjects as well as in patients with AIHA of the cold reactive types. CA bind to erythrocyte surface antigens at a temperature optimum of 0–4 °C. In contrast to polyclonal CA in healthy individuals, monoclonal CA often have a high-thermal amplitude, which contributes to their pathogenicity at temperatures approaching 37 °C. Binding of CA causes agglutination of erythrocytes and the antigen–antibody complex induces complement (C) activation and hemolysis. Essential clinical manifestations of primary CAD are hemolytic anemia and cold-induced circulatory symptoms. Exact estimates of the severity of anemia and the frequency of cold-induced symptoms, however, have not been provided until recent years.
== Antibody mutation == Mature lymphocytes are part of the specific immune system because they recognize previous invaders and assist the body in attacking these invaders. These cells have antibodies present on the surface of the extracellular membrane, which contribute to the destruction of the invader or antigen. An antibody is a large protein created by plasma cells and is also known as an immunoglobulin. It binds to a specific antigen to initiate an immune response. T-cell antibodies bind to antigens such as virus infected cells or tumor cells. In Lutzner cells, there is a mutation in the T-cell receptor that inhibits antigens like CD8 and CD7, but stimulates the over production of other antigens like CD4. This mutation is a clonal gene rearrangement at the TCR-γ gene. Clonal gene rearrangements create novel or new surface antibodies during early differentiation. Since these mutated antibodies are created early on, they are able to undergo mitosis and produce new T-cell lymphocytes that also contain the novel antigens. The abnormal quantity of T-cell receptors occurs because they are selected for since they express new qualities. CD4+ is the receptor that is selected for and increases in number in Lutzner cells. The neoplastic T-cells produce cytokines which active the expression of eosinophils and suppress the ability of T-cells to initiate an immune response. Since T-cell activity is lessened, the cells are not able to respond to invaders. Invaders are allowed to grow and produce lesions, and as the lesions increase in size the T-cell antigen is lost.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.